CTLA4 and large cell neuroendocrine carcinoma: Among patients with advanced LCNEC in the ICIs + Chemo group, five (35.71%) received PD-1 inhibitors, eight (57.14%) were treated with PD-L1 inhibitors, and one patient (7.14%) received a PD-1/CTLA-4 inhibitor.